Skip to content
Back to Parent Page

NexSys PCS® with Persona® Technology

Persona® Technology, a proprietary integrated plasma collection solution built upon the NexSys PCS® platform, is the first and only donor-tailored solution clinically shown to yield +9% to 12%1 more plasma per donation on average to maximize both cost-efficient output and patient impact.
Available in the US only.


The plasma collection system of the future

The Persona® Technology Nomogram Story

The simple nomogram in place since 1992 was based solely on an individual’s weight.2 It allowed three plasma collection volumes according to whether the donor fell into one of three different weight ranges.

The Persona® Technology Nomogram is a novel, personalized percent plasma nomogram based on body mass index and hematocrit, enabling a more tailored collection target using individual donor characteristics.

In a multicenter, prospective, double-blinded, randomized controlled clinical trial involving 3,443 donors who underwent 23,137 plasma donations - one of the largest plasmapheresis trials ever conducted:

  • Using NexSys PCS® with Persona® Technology resulted in an average increase in volume of plasma collected per donation across the study population.

  • The number of repeat donations was not impacted and increasing plasma collection volume up to a maximum of 1,000 mL was well tolerated in eligible donors.

Related Training & Resources

Back to top
Haemonetics Education Portal

Education Portal

Explore elearning, videos, and other resources by logging in to the Education Portal. Designed to enhance your knowledge of the plasma collection industry, the Education Portal features useful information about the NexSys PCS® system, plasma software solutions, and more. With one login, you can search through all related content, providing efficiency getting the training and answers you need quickly!

Launch the Education Portal
1. Based on baseline device, software configuration and donor population.
2. FDA Memorandum: Volume Limits – Automated Collection of Source Plasma (11/4/92). Center for Biologics Evaluations and Research. US Food and Drug Administration.
†Demonstrated by the IMPACT study, a multicenter, prospective, double-blinded, randomized controlled clinical trial involving 23,137 plasma donations.